The Latest Breaking News from Lilly

Eli Lilly Launches Discount Anti-Obesity Drug

The company claims the Zepbound doses cost 50% less than competing drugs

International Business Times · Aug 27, 2024

Weight loss drug Tirzepatide cuts diabetes risk by an astonishing 94%, says study

A new study on the popular weight loss drug Tirzepatide, manufactured by American pharmaceutical company Eli Lilly, has found the drug could dramatically cut the risk of developing type 2 diabetes in obese or overweight people with prediabetes, compared with a placebo.

The Times of India · Aug 21, 2024

Up 58% YTD, is Eli Lilly Stock Still a Buy?

The pharmaceutical giant has already delivered massive gains this year, but Wall Street analysts have only gotten more bullish on the maker of Mounjaro and Zepbound.

Barchart · Aug 19, 2024

NBCU to Offer First-Ever Commercial-Free Hour During Live Coverage of the Olympics Opening Ceremony

The commercial-free hour, which begins at 1:30 p.m. ET on July 26, is sponsored by Coke, Delta, Eli Lilly, Toyota, Visa, and Xfinity

TV Tech · Jul 24, 2024

Ozempic knockoffs flood US market thanks to ‘blind spot’ in FDA rules

Pharmacy alliance president counters that ‘it’s an intentional policy’ so patients don’t go without medication

The Guardian - US · Jul 22, 2024

Weight-loss war heats up as Wegovy rival found to lead to faster and greater results

Shares in Novo Nordisk were down 1.1% after the study

The Independent UK · Jul 9, 2024

A weight loss miracle! New shot does better than Ozempic and Wegovy during trials

Tirzepatide, which is sold under the brand names Mounjaro and Zepbound – which treat diabetes and weight loss, respectively – leads to more weight loss than semaglutide, new research has shown

The Independent UK · Jul 8, 2024

What Is Kisunla? Know All About New FDA-Approved Drug For Alzheimer's Disease

Kisunla manufactured by Eli Lilly could significantly slow cognitive decline in people with early symptomatic Alzheimer's disease, according to results of the company's clinical trials.

Medical Daily · Jul 3, 2024

FDA Approves New Alzheimer's Drug To Slow Disease Progression

FDA approves Eli Lilly's donanemab for early Alzheimer's, offering hope for patients and caregivers. Treatment priced at 5 per vial.

Top News · Jul 3, 2024

FDA approves second Alzheimer’s drug that can slow onset of disease

Eli Lilly says Kisunla demonstrated ‘meaningful results’ for people showing early symptoms of the disease

The Guardian - US · Jul 2, 2024